Martin Dubuc, general manager of Biogen France, discusses the company’s strong leadership in neurosciences, its commitment to pioneering the high-risk field despite the withdrawal of many industry players, the strategy to keep MS at the core of its business while developing next-generation treatments in areas like Alzheimer’s, and the important role that France and the affiliate play for Biogen globally.
In order to be successful in neuroscience, we have to be focused and entirely dedicated as experts.
